Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 — The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Enhertu demonstrated a median progression-free survival of 13.2 …
WEBJun 2, 2024 — With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
Enhertu demonstrated statistically significant and clinically ...
WEBApr 29, 2024 — With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
Enhertu demonstrated clinically meaningful survival across …
WEBOct 23, 2023 — AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population
ENHERTU® Showed Substantial Clinical Activity in Patients with …
WEBSep 13, 2024 — DESTINY-Breast12 is an open-label, multicenter, phase 3b/4 clinical trial designed to evaluate the efficacy and safety of ENHERTU (5.4 mg/kg) in patients with previously treated advanced/metastatic HER2 positive breast cancer.
ENHERTU - Business Wire
WEB2 days ago — The safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks ...
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
WEB1 day ago — The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025. News
ENHERTU - Business Wire
WEB2 days ago — The safety of ENHERTU was evaluated in 101 patients with HER2-mutant unresectable or metastatic NSCLC who received ENHERTU 5.4 mg/kg intravenously once every three weeks until disease progression ...
AZ, Daiichi's Enhertu cleared by FDA in wide range of tumors
WEBApr 8, 2024 — The latest nod marks Enhertu’s fifth approved indication in the U.S. The ADC, which won its original nod in 2019, is also cleared to treat HER2-positive and HER2-low breast cancer, plus gastric...
ENHERTU ® Granted Two Breakthrough Therapy ... - Business Wire
WEBAug 31, 2023 — Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colorectal cancer. ENHERTU has now been...